Orlistat e rischio cardiovascolare

Translated title of the contribution: Orlistat and cardiovascular risk

Giuseppe Derosa, Mario N. Piccinni

Research output: Contribution to journalArticle

Abstract

Long term weight reduction has been associated with favourable effects on many cardiovascular risk factors. Orlistat administration in obese patients has been associated with improvement of glucose tolerance and reduction in the incidence of type 2 diabetes. Furthermore, well conducted trials demonstrated the ability of orlistat to reduce many cardiovascular risk factors: hypertension, total and low density lipoprotein (LDL) cholesterol levels and low density lipoprotein cholesterol/high density lipoprotein cholesterol ratio (LDL/HDL ratio). More recently orlistat has yet been involved in the modulation of some inflammatory markers. Data available from intervention trials suggest that weight loss reduces coronary heart disease risk factors in obese persons and the risk factor reduction is significantly enhanced with administration of orlistat.

Original languageItalian
Pages (from-to)169-178
Number of pages10
JournalTrends in Medicine
Volume6
Issue number2
Publication statusPublished - Apr 2006

Fingerprint

LDL Cholesterol
Weight Loss
Aptitude
Risk Reduction Behavior
Type 2 Diabetes Mellitus
HDL Cholesterol
Coronary Disease
Hypertension
Glucose
orlistat
Incidence

ASJC Scopus subject areas

  • Internal Medicine
  • Pharmacology (medical)

Cite this

Derosa, G., & Piccinni, M. N. (2006). Orlistat e rischio cardiovascolare. Trends in Medicine, 6(2), 169-178.

Orlistat e rischio cardiovascolare. / Derosa, Giuseppe; Piccinni, Mario N.

In: Trends in Medicine, Vol. 6, No. 2, 04.2006, p. 169-178.

Research output: Contribution to journalArticle

Derosa, G & Piccinni, MN 2006, 'Orlistat e rischio cardiovascolare', Trends in Medicine, vol. 6, no. 2, pp. 169-178.
Derosa G, Piccinni MN. Orlistat e rischio cardiovascolare. Trends in Medicine. 2006 Apr;6(2):169-178.
Derosa, Giuseppe ; Piccinni, Mario N. / Orlistat e rischio cardiovascolare. In: Trends in Medicine. 2006 ; Vol. 6, No. 2. pp. 169-178.
@article{9c9847e917ed4673ab4409275bfabdd9,
title = "Orlistat e rischio cardiovascolare",
abstract = "Long term weight reduction has been associated with favourable effects on many cardiovascular risk factors. Orlistat administration in obese patients has been associated with improvement of glucose tolerance and reduction in the incidence of type 2 diabetes. Furthermore, well conducted trials demonstrated the ability of orlistat to reduce many cardiovascular risk factors: hypertension, total and low density lipoprotein (LDL) cholesterol levels and low density lipoprotein cholesterol/high density lipoprotein cholesterol ratio (LDL/HDL ratio). More recently orlistat has yet been involved in the modulation of some inflammatory markers. Data available from intervention trials suggest that weight loss reduces coronary heart disease risk factors in obese persons and the risk factor reduction is significantly enhanced with administration of orlistat.",
keywords = "Cardiovascular risk, Diabetes, Obesity, Orlistat, Weight reduction",
author = "Giuseppe Derosa and Piccinni, {Mario N.}",
year = "2006",
month = "4",
language = "Italian",
volume = "6",
pages = "169--178",
journal = "Trends in Medicine",
issn = "1594-2848",
publisher = "Pharma Project Group Edizioni Scientifiche (PPG)",
number = "2",

}

TY - JOUR

T1 - Orlistat e rischio cardiovascolare

AU - Derosa, Giuseppe

AU - Piccinni, Mario N.

PY - 2006/4

Y1 - 2006/4

N2 - Long term weight reduction has been associated with favourable effects on many cardiovascular risk factors. Orlistat administration in obese patients has been associated with improvement of glucose tolerance and reduction in the incidence of type 2 diabetes. Furthermore, well conducted trials demonstrated the ability of orlistat to reduce many cardiovascular risk factors: hypertension, total and low density lipoprotein (LDL) cholesterol levels and low density lipoprotein cholesterol/high density lipoprotein cholesterol ratio (LDL/HDL ratio). More recently orlistat has yet been involved in the modulation of some inflammatory markers. Data available from intervention trials suggest that weight loss reduces coronary heart disease risk factors in obese persons and the risk factor reduction is significantly enhanced with administration of orlistat.

AB - Long term weight reduction has been associated with favourable effects on many cardiovascular risk factors. Orlistat administration in obese patients has been associated with improvement of glucose tolerance and reduction in the incidence of type 2 diabetes. Furthermore, well conducted trials demonstrated the ability of orlistat to reduce many cardiovascular risk factors: hypertension, total and low density lipoprotein (LDL) cholesterol levels and low density lipoprotein cholesterol/high density lipoprotein cholesterol ratio (LDL/HDL ratio). More recently orlistat has yet been involved in the modulation of some inflammatory markers. Data available from intervention trials suggest that weight loss reduces coronary heart disease risk factors in obese persons and the risk factor reduction is significantly enhanced with administration of orlistat.

KW - Cardiovascular risk

KW - Diabetes

KW - Obesity

KW - Orlistat

KW - Weight reduction

UR - http://www.scopus.com/inward/record.url?scp=33646511113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646511113&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:33646511113

VL - 6

SP - 169

EP - 178

JO - Trends in Medicine

JF - Trends in Medicine

SN - 1594-2848

IS - 2

ER -